Member Login
  1. Stocks
    2. /
  2. Renalytix AI plc (LSE: RENX)
    3. /

LSE:RENX (Renalytix AI plc)

About RENX

Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The company's lead product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Financial Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

    • Renalytix AI plc (LSE: RENX) Latest News

    Hand arranging wood block stacking as step stair on paper pink background
    Investing Articles

    Why has the Renalytix AI share price jumped?

    | Christopher Ruane

    On Thursday, the Renalytix AI share price grew by double digits. Christopher Ruane explains why and what he'll do on…

    Read more »

    Investing Articles

    £500 to invest? Here’s how I’d look to make a 1,000% return investing in shares

    | Andy Ross

    Investing in shares can be hugely rewarding. To make big returns Andy Ross looks to smaller, more agile companies.

    Read more »

    woman sitting in wheelchair at the table and looking at computer monitor while talking on mobile phone and drinking coffee at home
    Investing Articles

    The Renalytix share price more than doubled in a year: what I’d do now

    | Christopher Ruane

    The Renalytix share price more than doubled in a year -- I know what I'll do now.

    Read more »

    Investing Articles

    The price of this UK tech share is up over 80% in just the last month. Would I buy?

    | Andy Ross

    This UK tech share, which provides artificial intelligence diagnostics, has leapt recently in price and there could be potentially a…

    Read more »